Ulcerative colitis (UC)

Microbiome
#Financing #Microbiotica #Phase II trial #Ulcerative colitis (UC)

Microbiotica raises £36 million to advance into Phase II

Biopharma company Microbiotica has closed £36 million in Series C financing to support the advancement of its treatment for ulcerative colitis. The financing was led by British Business Bank, with participation from Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, and Seventure Partners. All existing Series B investors participated in… Read More

#Business & Investment #News

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 30 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers uncovered clues explaining risks of heart disease, lung disease, Covid-19 and… Read More

#Podcasts

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 23 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, results showed the new Wegovy pill could help patients lose 17% of… Read More

#Podcasts

#AI #ASCO #Cancer Research UK #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

This week in Drug Discovery (15 June – 19 June) 

News round-up for 15 June – 19 June by Bruno Quinney, Content Team at DDW.  This week, results show the new Wegovy pill could help patients lose 17% of their body weight. Elsewhere, advances have been made in both cancer treatment and cancer research.  The top stories:     … Read More

#News

Blood tests in laboratory
#Clinical trial #Ulcerative colitis (UC)

Ulcerative colitis treatment shows best-in-class potential 

An anti-TL1A has demonstrated its potential to be a best-in-class treatment for ulcerative colitis.  Biotechnology company Spyre Therapeutics reported results from the Phase II SKYLINE trial evaluating SPY002, an extended half-life investigational antibody targeting TL1A. TL1A is an upstream cytokine implicated in chronic inflammation and fibrosis in inflammatory… Read More

#News

ulcerative colitis
#Biotech #Clinical trial #Ulcerative colitis (UC)

Spyre Therapeutics reports positive data for UC treatment 

Biotechnology company Spyre Therapeutics has reported positive results for its treatment for moderate-to-severely-active ulcerative colitis (UC).  SPY001, a potential best-in-class anti-α4β7, met its primary endpoint in a Phase II trial, with a significant reduction of 9.2 points from baseline at Week 12 in Robart’s Histopathology Index (RHI) score. Read More

#News

#Biosimilars #Cancer research #Cancer Research Horizons #Cerebral Palsy #Clinical trial #Crohn's disease #Depression #European Union #Novo Nordisk #Obesity #Psychedelics #Thermo Fisher Scientific #Ulcerative colitis (UC)

DDW Highlights: 24 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers found an unexpected drug could help treat depression. Elsewhere, a new company is… Read More

#Podcasts

#Biosimilars #Cancer research #Cancer Research Horizons #Cerebral Palsy #Clinical trial #Crohn's disease #Depression #European Union #Novo Nordisk #Obesity #Psychedelics #Thermo Fisher Scientific #Ulcerative colitis (UC)

This week in Drug Discovery (16 – 20 February) 

News round-up for 16 – 20 February by Bruno Quinney, Content Team at DDW.  This week in DDW, an unexpected drug could help treat depression. Elsewhere, a new company is set to advance a cerebral palsy therapy.  The top stories:    Psychedelic drug could help treat depression … Read More

#News

Blood tests in laboratory
#Clinical trial #Crohn's disease #Ulcerative colitis (UC)

Infliximab could restore disease response after drug holiday 

Subcutaneous (SC) infliximab could restore and maintain disease response in most Crohn’s disease (CD) and ulcerative colitis (UC) patients, data shows.  Results announced by biopharmaceutical company Celltrion demonstrated that initiating subcutaneous (SC) infliximab after a treatment interruption, following intravenous (IV) infliximab induction, helps patients with Crohn’s disease (CD) and ulcerative colitis… Read More

#News

Europe
#Arthritis #Biosimilars #Europe #NHS #Ulcerative colitis (UC)

Alvotech launches Simponi biosimilar in Europe 

Biotechnology company Alvotech has announced the European launch of its first-in-market biosimilar to Simponi (golimumab).  AVT05, known as Gobivaz, is a prefilled syringe and autoinjector used for the treatment of adults with rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, as well as in children with ulcerative colitis. Gobivaz becomes the first marketed biosimilar to… Read More

#News

Blood tests in laboratory
#Crohn's disease #European Commission #Ulcerative colitis (UC)

World’s first liquid infliximab formulation approved for market 

The European Commission (EC) has granted marketing authorisation for the world’s first liquid formulation of infliximab.  Remsima is an intravenous liquid formulation used to treat autoimmune diseases including Crohn’s disease and ulcerative colitis. Remsima was first approved in September 2013 and launched in major EU countries in 2015 as a… Read More

#News

ulcerative colitis
#Crohn's disease #Inflammatory Bowel Disease #NHS Scotland #Ulcerative colitis (UC)

Inflammatory bowel disease drug approved for use in NHS Scotland 

The Scottish Medicines Consortium (SMC) has accepted Tremfya (guselkumab) for use in NHS Scotland for the treatment of adult patients with moderately to severe Crohn’s disease and ulcerative colitis.  Guselkumab is the first IL-23 inhibitor that could offer a fully subcutaneous induction and maintenance regimen in Crohn’s disease and ulcerative… Read More

#News #Regulatory

#Cancer research #Gut microbiome #Microbiotica #Ulcerative colitis (UC)

Unravelling the modes of action of microbiome therapies

Tim Sharpington, Chief Executive Officer at Microbiotica, and Matthew Robinson, SVP Research, Microbiotica, discuss the opportunities for precision-based microbiome therapeutics and which diseases could benefit the most from this approach.   The development of genetic techniques to analyse the microbiome has triggered a massive expansion of research into our relationship with… Read More

#Exclusive Content

CAR-T cell therapy
#Autoimmune disease #CAR-T #Cell therapy #Immunotherapy #Ulcerative colitis (UC)

First use of CAR-T therapy to treat ulcerative colitis

A team of physicians at the German Center for Immunotherapy at Erlangen University Hospital has succeeded for the first time worldwide in treating a 21-year-old female patient with therapy-resistant, severe chronic inflammatory bowel disease (ulcerative colitis) using cell therapy with CD19 CAR-T cells.  The 21-year-old patient had… Read More

#Editor's Choice #News

ulcerative colitis
#European Commission #Johnson & Johnson #Monoclonal antibodies #Ulcerative colitis (UC)

Guselkumab approved in the EU for ulcerative colitis

The European Commission (EC) has approved a marketing authorisation (MA) for Johnson & Johnson’s Tremfya (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).  It is approved in patients who had an inadequate response, lost response, or were intolerant to either conventional therapy or… Read More

#News #Regulatory

The microbiome
#Gut microbiome #Microbiome #Microbiotica #Preclinical development #Ulcerative colitis (UC)

Preclinical data reveals mechanism behind microbiome therapy

Microbiotica has revealed new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC).   The data were shared at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held 18-21 February in Banff, Canada and at the European… Read More

#News